"The session will review the current trends and major factors affecting the competitiveness of the biopharmaceutical industry in Europe. Senior European policymakers and top biotechnology company executives will present and discuss key aspects of the business, regulatory and scientific environment in which biopharmaceutical players compete in the European Union. The panel will address economic incentive schemes, collaborative R&D programs, access to financing and the outlook to growth of the biopharmaceutical sector in Europe and necessary ingredients for success."

Objective1: Outline how we can strengthen transatlantic cooperation between Europe and the United States.

Objective2: Promote scientific exchange and efficient collaboration between industry, academia and governments.

Objective3: Discuss how to develop mechanisms for international sharing of medical countermeasures.